研究目的：
This study is conducted to explore the safety and efficacy of anlotinib,a tyrosine kinase inhibitors of vascular endothelial growth factor receptor 2（VEGFR）、FGFR（fibroblast growth factor receptor）,platelet-derived growth factor receptor（PDGFR） and tumor cell proliferation related kinase c-Kit,combined with platinum plus pemetrexed in T790M mutation negative metastatic non-squamous non-small cell lung cancer(NSCLC) after the failure of EGFR-TKI.
